| Objective To investigate the effects of Xuezhikang capsules on cytokine in myocardial ischemia-reperfusion injury (MIRI) rats.Methods Thirty-two SD rats were randomized into four groups, normal group, sham group, MIRI group and Xuezhikang pretreatment group. The rats of Xuezhikang group were treated with Xuezhikang(0.09g/kg, gastric gavage) and other groups were treated with the same amount of saline continuous for 7 days.To build the rats myocardial ischemia-reperfusion injury model. The left anterior descending branches of rats of MIRI group and Xuezhikang pretreatment group were ligated for 30 minutes and reperfusion for 60 minutes Blood samples were extracted from the abdominal vein of rats, and the sera were collected to measurement the interleukin-1β, interleukin-4, interleukin-8, tumor necrosis factor alpha(TNF-a), creatine kinase-MB (CK-MB), TroponinI. MI size was determined by Evans Blue staining. And observe the change of the cardiac muscle cell under the microscope.Result Compared with the normal group and sham group, the levels of serum IL-1β, IL-8,TNF-a,CK-MB,cTNI in Ischemia reperfusion injury group were higher significantly (F=48.72～351.07,Q=0.25～41.65,P<0.01), and compared with Ischemia-reperfusion injury group, tthe levels of serum IL-1β, IL-8,TNF-a,CK-MB,cTNI were lower significantly in the Xuezhikang pretreatment groups (F=48.72～351,Q=0.35～32.65,P<0.05), and the level of serum IL-4 in the Xuezhikang pretreatment groups were higher significantly than Ischemia-reperfusion injury group (F=197.89,Q=0.37～29.4).The size of MI in Xuezhikang pretreatment groups is smaller than Ischemia reperfusion injury group (F=231.26,Q=17.21, P<0.05)Conclusion Xuezhikang can protect myocardial ischemia-reperfusion injury by reducing serum IL-1β,IL-8,TNF-a and enhancing serum IL-4, which could reduce systemic inflammatory responses in rats.
|
PDF Full Text Request